MADELEINE CRAWFORD: Open Payments
NPI 1770117335 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 28 payments from 14 companies in 2025. Trend: 2023 $619 · 2024 $499 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $139 |
| ABBVIE INC. | 4 | $101 |
| Lilly USA, LLC | 3 | $59 |
| SANOFI-AVENTIS U.S. LLC | 2 | $45 |
| Astellas Pharma US Inc | 1 | $30 |
| BIOTRONIK NRO, Inc. | 1 | $29 |
| MicroTransponder, Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| SI-BONE, INC. | 1 | $25 |
| Exact Sciences Corporation | 1 | $23 |
Products named: MOUNJARO, Rybelsus, TZIELD, Wegovy, DALVANCE, UBRELVY, QULIPTA, Veozah.
Industry payments across CA — which companies pay providers there.
